Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00132171
Status:
COMPLETED
Last Update Posted:
2021-03-18
First Post:
2005-08-18
Brief Title:
Helicobacter Pylori Eradication With a New Sequential Treatment
Sponsor:
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Organization:
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Study Overview
Official Title:
High Eradication Rates of Helicobacter Pylori With a New Sequential Treatment
Status:
COMPLETED
Status Verified Date:
2021-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Eradication rates of Helicobacter pylori H pylori with standard triple therapy are disappointing and studies from several countries confirm this poor performance The study aimed to assess the eradication rate of a new sequential treatment regimen compared with conventional triple therapy for the eradication of H pylori infection
Detailed Description:
One thousand and forty-nine dyspeptic patients were studied prospectively H pylori-infected patients were randomized to receive 10-day sequential therapy rabeprazole 20 mg twice daily plus amoxicillin 1 g twice daily for the first 5 days followed by rabeprazole 20 mg clarithromycin 500 mg and tinidazole 500 mg all twice daily for the remaining 5 days or standard 7-day therapy corrected rabeprazole 20 mg clarithromycin 500 mg and amoxicillin 1 g all twice daily H pylori status was assessed by histology rapid urease test and 13C-urea breath test at baseline and 6 weeks or more after completion of treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None